Unveiling the Impact of GLP-1 Agonists on US Dialysis Medical Devices: A Comprehensive Overview
The Growing Burden of Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD): A Critical Overview
The United States is grappling with a significant health crisis: the growing burden of CKD and ESRD. Between 2017 and 2020, approximately 14% of US adults were affected by CKD, and over 815,000 individuals were living with ESRD. These figures are alarming, given that CKD is a progressive loss of kidney function over time, and ESRD represents its terminal phase, where the kidneys can no longer sustain life without dialysis or transplant. The 2024 USRDS report underscores the scale of the problem, highlighting the need for innovative solutions.
The Role of GLP-1 Agonists: A Potential Game-Changer
The question on everyone's mind is: could GLP-1 receptor agonists, given before or even during ESRD, meaningfully improve outcomes for this high-risk population? A 2024 clinical trial titled 'A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease' found that the decline in kidney function, measured by glomerular filtration rate (eGFR), was slower in the semaglutide group compared to the placebo group. The risk of major cardiovascular events in patients on semaglutide was 18% lower, and the risk of death caused by these events was 20% lower.
In January 2025, the FDA approved Ozempic (semaglutide) for use in reducing the risk of kidney failure and disease progression, and heart problems associated with diabetes patients with CKD. The EMA also allowed Ozempic to add reduction for events related to kidney disease to its label. While Ozempic is not a cure, it can slow the progression to ESRD and decrease major cardiovascular events and deaths associated with them.
The Impact on Dialysis Care and Medical Devices
The impact on dialysis care and medical devices is intriguing. While Ozempic will not cure CKD, it functionally slows disease progression, leading to more patients progressing to stage 5 or ESRD, where dialysis or transplants are needed for patient survival. This could result in a rise in the medical devices market, from human leukocyte antigen testing for organ matching to dialysers and dialysis machines for dialysis care.
The Controversial Question: Will GLP-1 Agonists Shrink the Prevalence of ESRD?
One controversial question is whether the use of GLP-1 agonists, such as Ozempic, prior to CKD onset will actually shrink the prevalence of ESRD. Given that one in three adults with diabetes (both type 2 and type 1) has CKD, treating this population for type 2 diabetes with Ozempic to achieve diabetes remission may prevent patients from developing CKD in the first place. However, the uncertain long-term population effects and access limitations (such as payer coverage) mean that both clinicians and medical device companies must plan for mixed scenarios in service demand and patient access.
The Future of Dialysis Care and Medical Devices
The future of dialysis care and medical devices is uncertain, but one thing is clear: the broader use of GLP-1s for diabetes remission could ultimately reduce new CKD cases. As such, both clinicians and medical device companies must be prepared for a range of scenarios, from increased demand for dialysis equipment and human leukocyte antigen testing to a decrease in the need for transplants. The key is to stay proactive with real-time data and expert analysis, ensuring that policy changes and market shifts do not catch us off guard.
